Regeneus Limited
(ASX:RGS) has scored ethics approval to collect stem cells from human donors for use in the production of its new product.
The regenerative medicine company says the allogeneic off-the-shelf stem cell product is for the treatment of osteoarthritis.
Ethics approval will now enable Regeneus to start manufacturing the cells for its first-in-man clinical trial.
The trial will assess initial safety and preliminary efficiency in human volunteers with knee osteoarthritis.
Regeneus says this is an important first step in taking its human allogeneic product for osteoarthritis through the regulatory approval process.
The news comes just days after Regeneus partnered with US specialist veterinary vaccine manufacturer Hennessy Research for the production of Regeneus’ canine cancer immunotherapy, Kvax.
Regeneus reported a net loss of $6.4 million in the first half of the 2014 financial year.
